Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.


Treatment of CMML remains a clinical challenge, with no drug demonstrating clear clinical benefit. Even if azacitidine is approved in the treatment of CMML, its role remains disputed. We report a cohort of 76 CMML patients (according to WHO classification) treated with azacitidine in 3 programs (French AZA compassionate program, Cleveland Clinic Foundation… (More)
DOI: 10.1016/j.leukres.2013.01.004


4 Figures and Tables